EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model

Peng, Wei; Huang, Xunwu; Yang, Dazhi

doi:10.1016/j.intimp.2014.05.013

Cited by 5 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, treatment of mice using DCs pulsed with the EWS-FLI1 epitope led to the rejection of ES in vivo. 101 A number of clinical trials have been performed investigating different types of vaccines and adjuvants in patients with ES (table 1). DCs pulsed with peptides derived from the EWS-FLI1 fusion protein were used in some of the initial clinical trials.…”

Section: Cancer Vaccines For Esmentioning

confidence: 99%

Role of immunotherapy in Ewing sarcoma

Morales

Olson

Iglesias

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

Ewing sarcoma (ES) is thought to arise from mesenchymal stem cells and is the second most common bone sarcoma in pediatric patients and young adults. Given the dismal overall outcomes and very intensive therapies used, there is an urgent need to explore and develop alternative treatment modalities including immunotherapies. In this article, we provide an overview of ES biology, features of ES tumor microenvironment (TME) and review various tumor-associated antigens that can be targeted with immune-based approaches including cancer vaccines, monoclonal antibodies, T cell receptor-transduced T cells, and chimeric antigen receptor T cells. We highlight key reasons for the limited efficacy of various immunotherapeutic approaches for the treatment of ES to date. These factors include absence of human leukocyte antigen class I molecules from the tumor tissue, lack of an ideal surface antigen, and immunosuppressive TME due to the presence of myeloid-derived suppressor cells, F2 fibrocytes, and M2-like macrophages. Lastly, we offer insights into strategies for novel therapeutics development in ES. These strategies include the development of gene-modified T cell receptor T cells against cancer–testis antigen such as XAGE-1, surface target discovery through detailed profiling of ES surface proteome, and combinatorial approaches. In summary, we provide state-of-the-art science in ES tumor immunology and immunotherapy, with rationale and recommendations for future therapeutics development.

show abstract

Section: Cancer Vaccines For Esmentioning

confidence: 99%

Role of immunotherapy in Ewing sarcoma

Morales

Olson

Iglesias

et al. 2020

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…In a study discussing peptide epitope derived from Fli-1 protein, the authors found that effectors induced by the peptide are able to generate IFNγ and are able to lyse the Fli-1 + tumor cell line. 13 Mice models with Ewing's sarcoma were treated with DCs that were pulsed with Fli-1 epitope, showing that there was rejected lethal tumor F I G U R E 1 Role of Fli-1 in different immune cells. Fli-1 may bind to CXLC10, CXCR3, and CXCL13, and then regulate different immune cells proliferation, differentiation, and cytokines, chemokines production.…”

Section: Impact Of Fli-1 On Immune Cellsmentioning

confidence: 99%

“…It is known that most of the Ewing's sarcoma family showed high expression of Fli‐1, which suggested that Fli‐1 may be a potential target for cytotoxic T‐lymphocyte responses. In a study discussing peptide epitope derived from Fli‐1 protein, the authors found that effectors induced by the peptide are able to generate IFNγ and are able to lyse the Fli‐1 + tumor cell line 13 . Mice models with Ewing's sarcoma were treated with DCs that were pulsed with Fli‐1 epitope, showing that there was rejected lethal tumor inoculation.…”

Section: Function Of Fli‐1 On Immune Cells and Non‐immune Cellsmentioning

confidence: 99%

Targeting Fli‐1 and chemokine axis CXCL10/CXCL13/CXCR3 in systemic lupus erythematosus and lupus nephritis

Zhu

2024

Int J of Rheum Dis

View full text Add to dashboard Cite

Fli‐1 is a critical factor involved in hematopoietic stem cells, vascular endothelial cells apoptosis, and differentiation. Similarly, Fli‐1 regulates immune cell proliferation and differentiation, such as T cells, B cells, and monocytes. Regarding T/B cell dysfunction, SLE including LN is recognized to be associated with abnormal expression and function of Fli‐1. Moreover, three ligands of Fli‐1 including CXCL10 (C‐X‐C motif chemokine ligand 10), CXCR3 (C‐X‐C motif chemokine receptor 3), CXCL13 are widely discussed in SLE/LN. In this comprehensive review, we not only discussed Fli‐1 within SLE/LN pathogenesis, but also discussed the effects of CXCL10, CXCR3, and CXCL13 on SLE/LN development. Furthermore, we discussed how Fli‐1 regulates CXCL10, CXCR3, and CXCL13, and then involved in lupus development. It is possible that the Fli‐1 axis might be a potential target in SLE and LN.

show abstract

“…Specifically, CD103+ cDC1s have been identified as playing a crucial role in T cell activation and enhancing anti-tumor immune responses, particularly when combined with ICIs, exhibiting notable effectiveness against osteosarcoma ( Zhou et al, 2020b ). Additionally, tumor lysate-pulsed DC vaccines effectively activate the immune system, inhibiting osteosarcoma growth ( Kawano et al, 2015 ), while DCs pulsed with EWS/FLI-l peptide epitopes exhibit significant capabilities in tackling Ewing’s sarcoma ( Peng et al, 2014 ). Radiofrequency ablation (RFA) combined with OK-432 injection significantly increases intratumoral amounts of DCs, affirming the critical role of DCs in inducing distal immune effects and anti-tumor immune responses ( Iwai et al, 2020 ).…”

Section: Immune Cellsmentioning

confidence: 99%

Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies

Liang,

Cui,

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Osteosarcoma, a malignant bone tumor predominantly affecting children and adolescents, presents significant therapeutic challenges, particularly in metastatic or recurrent cases. Conventional surgical and chemotherapeutic approaches have achieved partial therapeutic efficacy; however, the prognosis for long-term survival remains bleak. Recent studies have highlighted the imperative for a comprehensive exploration of the osteosarcoma immune microenvironment, focusing on the integration of diverse immunotherapeutic strategies—including immune checkpoint inhibitors, tumor microenvironment modulators, cytokine therapies, tumor antigen-specific interventions, cancer vaccines, cellular therapies, and antibody-based treatments—that are directly pertinent to modulating this intricate microenvironment. By targeting tumor cells, modulating the tumor microenvironment, and activating host immune responses, these innovative approaches have demonstrated substantial potential in enhancing the effectiveness of osteosarcoma treatments. Although most of these novel strategies are still in research or clinical trial phases, they have already demonstrated significant potential for individuals with osteosarcoma, suggesting the possibility of developing new, more personalized and effective treatment options. This review aims to provide a comprehensive overview of the current advancements in osteosarcoma immunotherapy, emphasizing the significance of integrating various immunotherapeutic methods to optimize therapeutic outcomes. Additionally, it underscores the imperative for subsequent research to further investigate the intricate interactions between the tumor microenvironment and the immune system, aiming to devise more effective treatment strategies. The present review comprehensively addresses the landscape of osteosarcoma immunotherapy, delineating crucial scientific concerns and clinical challenges, thereby outlining potential research directions.

show abstract

EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model

Cited by 5 publications

References 39 publications

Role of immunotherapy in Ewing sarcoma

Role of immunotherapy in Ewing sarcoma

Targeting Fli‐1 and chemokine axis CXCL10/CXCL13/CXCR3 in systemic lupus erythematosus and lupus nephritis

Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies

Contact Info

Product

Resources

About